logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
I

Ichinosuke Hyodo

nho shikoku cancer center
H指数:50
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable advanced pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel therapy

一项关于不可切除的晚期胰腺癌患者接受一线吉西他滨联合白蛋白结合型紫杉醇治疗的多中心前瞻性观察研究，采用EQ-5D-5L和G8健康评估问卷进行健康评估。

international journal of oncology
IF2.8
2025-02-270
PRE
Hino, Kaori; Nishina, Tomohiro; Koizumi, Mitsuhito; Marui, Kaori; Kokubu, Masahito; Numata, Yuki; Imamura, Yoshiki; Kanemitsu-Okada, Kozue; Otsuru, Toru; Kuroda, Taira; Ohno, Yoshinori; Asagi, Akinori; Miyata, Hideki; Yokota, Tomoyuki; Kumagi, Teru; Hyodo, Ichinosuke; Ikeda, Yoshio
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G
TARGETED ONCOLOGY
IF4
2024-03-010
OAAI
Matsumoto, Toshihiko; Yamamoto, Yoshiyuki; Kotaka, Masahito; Masuishi, Toshiki; Tsuji, Yasushi; Shoji, Hirokazu; Hirata, Kenro; Tsuduki, Takao; Makiyama, Akitaka; Izawa, Naoki; Takahashi, Naoki; Tsuda, Masahiro; Yasui, Hisateru; Ohta, Takashi; Kito, Yosuke; Otsu, Satoshi; Hironaka, Shuichi; Yamazaki, Kentaro; Boku, Narikazu; Hyodo, Ichinosuke; Yoshimura, Kenichi; Muro, Kei
A randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer: WJOG8315G
ANNALS OF ONCOLOGY
IF65.4
2023-11-012
OA
Makiyama, Akitaka; Shoji, Hirokazu; Kawakami, Hisato; Tamura, Takao; Sugiyama, Keiji; Hara, Hiroki; Nagase, Michitaka; Nishikawa, Kazuo; Esaki, Taito; Izawa, Naoki; Nakamura, Masato; Ando, Takayuki; Miura, Yuji; Narita, Yukiya; Shimokawa, Mototsugu; Yamazaki, Kentaro; Hironaka, Shuichi; Hyodo, Ichinosuke; Muro, Kei
Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201)
BMC CANCER
IF3.4
2022-02-159
OAAI
Sadahiro, Sotaro; Sakamoto, Kazuhiro; Tsuchiya, Takashi; Takahashi, Takao; Ohge, Hiroki; Sato, Toshihiko; Kondo, Ken; Ogata, Yutaka; Baba, Hideo; Itabashi, Michio; Ikeda, Masataka; Hamada, Madoka; Maeda, Kiyoshi; Masuko, Hiroyuki; Takahashi, Keiichi; Sakamoto, Junichi; Kusano, Mitsuo; Hyodo, Ichinosuke; Taguri, Masataka; Morita, Satoshi
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)
TARGETED ONCOLOGY
IF4
2020-09-225
PREAI
Izawa, Naoki; Shitara, Kohei; Yonesaka, Kimio; Yamanaka, Takeharu; Yoshino, Takayuki; Sunakawa, Yu; Masuishi, Toshiki; Denda, Tadamichi; Yamazaki, Kentaro; Moriwaki, Toshikazu; Okuda, Hiroyuki; Kondoh, Chihiro; Nishina, Tomohiro; Makiyama, Akitaka; Baba, Hideo; Yamaguchi, Hironori; Nakamura, Masato; Hyodo, Ichinosuke; Muro, Kei; Nakajima, Takako Eguchi
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)

帕尼单抗加伊立替康与西妥昔单抗加伊立替康在氟嘧啶，伊立替康和奥沙利铂难治性KRAS野生型转移性结直肠癌患者中的随机II期研究 (WJOG 6510G)

EUROPEAN JOURNAL OF CANCER
IF7.1
2020-08-0115
PREAI
Sakai, Daisuke; Taniguchi, Hiroya; Sugimoto, Naotoshi; Tamura, Takao; Nishina, Tomohiro; Hara, Hiroki; Esaki, Taito; Denda, Tadamichi; Sakamoto, Takeshi; Okuda, Hiroyuki; Satoh, Taroh; Tsushima, Takahiro; Makiyama, Akitaka; Tsuda, Takashi; Hosokawa, Ayumu; Kuramochi, Hidekazu; Tokunaga, Shinya; Moriwaki, Toshikazu; Yasui, Hisateru; Ishida, Hiroyasu; Tsuji, Akihito; Otsu, Satoshi; Shimokawa, Hozumi; Baba, Eishi; Sato, Mikio; Matsumoto, Shigemi; Ozaki, Yukinori; Shinozaki, Katsunori; Tamagawa, Hiroshi; Goto, Masahiro; Kadowaki, Shigenori; Fujii, Hirofumi; Koh, Yasuhiro; Yamazaki, Kentaro; Hironaka, Shuichi; Kishimoto, Junji; Boku, Narikazu; Hyodo, Ichinosuke; Muro, Kei
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G)
GASTRIC CANCER
IF5.1
2020-02-0830
OAAI
Nakajima, Takako Eguchi; Yamaguchi, Kensei; Boku, Narikazu; Hyodo, Ichinosuke; Mizusawa, Junki; Hara, Hiroki; Nishina, Tomohiro; Sakamoto, Takeshi; Shitara, Kohei; Shinozaki, Katsunori; Katayama, Hiroshi; Nakamura, Shinichiro; Muro, Kei; Terashima, Masanori
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
BRITISH JOURNAL OF CANCER
IF6.8
2019-07-0941
OAAI
Oki, Eiji; Emi, Yasunori; Yamanaka, Takeharu; Uetake, Hiroyuki; Muro, Kei; Takahashi, Takao; Nagasaka, Takeshi; Hatano, Etsuro; Ojima, Hitoshi; Manaka, Dai; Kusumoto, Tetsuya; Katayose, Yu; Fujiwara, Toshiyoshi; Yoshida, Kazuhiro; Unno, Michiaki; Hyodo, Ichinosuke; Tomita, Naohiro; Sugihara, Kenichi; Maehara, Yoshihiko
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)
EUROPEAN JOURNAL OF CANCER
IF7.1
2019-01-0120
OAAI
Ioka, Tatsuya; Ueno, Makoto; Ueno, Hideki; Park, Joon Oh; Chang, Heung-Moon; Sasahira, Naoki; Kanai, Masashi; Chung, Ik Joo; Ikeda, Masafumi; Nakamori, Shoji; Mizuno, Nobumasa; Omuro, Yasushi; Yamaguchi, Taketo; Hara, Hiroki; Sugimori, Kazuya; Furuse, Junji; Maguchi, Hiroyuki; Furukawa, Masayuki; Fukuzawa, Kengo; Kim, Jun-Suk; Yukisawa, Seigo; Takeuchi, Masahiro; Okusaka, Takuji; Boku, Narikazu; Hyodo, Ichinosuke

研究方向

暂未获取到该数据
N
Narikazu Boku
H 指数:75论文数:815被引数:2.9万
T
Toshikazu Moriwaki
H 指数:29论文数:207被引数:4,537
T
Tomohiro Nishina
H 指数:48论文数:487被引数:1.0万
K
Kei Muro
H 指数:80论文数:1,040被引数:4.4万
Y
Yoshiyuki Yamamoto
H 指数:24论文数:263被引数:3,425
S
Shuichi Hironaka
H 指数:42论文数:248被引数:1.0万
H
Hirofumi Matsui
H 指数:41论文数:315被引数:5,512
K
Kensei Yamaguchi
H 指数:65论文数:921被引数:2.2万
T
Tsuyoshi Kaneko
H 指数:51论文数:798被引数:1.0万
T
Toshihiko Doi
H 指数:73论文数:830被引数:2.9万